[{"data":1,"prerenderedAt":158},["ShallowReactive",2],{"content-route-/en/research/probiotics-for-vvc-cochrane-2017":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":139,"alternates":149},"target","/en/research/probiotics-for-vvc-cochrane-2017","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":53,"body":57},"Probiotics alongside antifungals for vulvovaginal candidiasis","A Cochrane review found small short-term signals but no established durable benefit and excluded recurrent and higher-risk populations.","2026-07-15","Replaced an unsupported legacy probiotic summary with a revalidated draft of the selected Cochrane review.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":40,"limitations":45,"practicalChange":52},"xie-probiotics-vvc-cochrane-2017","Cochrane systematic review of randomized controlled trials","Nonpregnant outpatients with confirmed vulvovaginal candidiasis; trials involving recurrent VVC, diabetes, immunosuppression, immunosuppressive medication, or another vulvovaginal infection were excluded","10 trials with 1,656 participants; individual outcome analyses ranged from one to seven trials and 172 to 969 participants","supporting","This 10-trial synthesis makes the exact short-term effect estimates, low and very-low certainty, excluded recurrent and higher-risk populations, lack of durable cure, and missing cost-effectiveness outcomes auditable in one source-level summary.","/en/research/evidence/broad-candida-claims","Cochrane reports that none of the ten included trials was funded by the pharmaceutical industry; included-study disclosures varied.","One included probiotic trial reported that an author held patents associated with lactobacilli; review-level author conflicts were not identified in the accessible record.","2017-11-23",[38,39],"Short-term clinical resolution occurred in 286 of 347 participants receiving probiotics plus antifungals and 251 of 348 receiving antifungals alone (five trials, 695 participants).","At one month, relapse occurred in 10 of 202 participants receiving adjunct probiotics and 27 of 186 receiving antifungals alone (three trials, 388 participants); long-term clinical and mycological resolution were not clearly improved.",{"appliesTo":41,"doesNotApplyTo":43},[42],"Short-term group outcomes from adjunct probiotic regimens studied with conventional antifungals in nonpregnant outpatients with VVC",[44],"Recurrent VVC prevention, pregnancy, diabetes, immunosuppression, probiotic monotherapy, every strain or product, or durable resolution",[46,49],{"finding":47,"limitation":48},"Adjunct probiotics were associated with more short-term clinical cure and fewer relapses at one month.","Evidence was low or very low certainty because of high risk of bias, small samples, imprecision, and few trials per outcome.",{"finding":50,"limitation":51},"Ten trials included 1,656 participants.","All excluded recurrent and higher-risk populations, all used probiotics alongside antifungals, and no trial reported cost effectiveness.","No practical change. The review does not establish durable benefit, recurrence prevention, monotherapy benefit, or a recommendation for a probiotic product or strain.",[54],{"group":55,"route":33,"label":56},"evidence","Broad Candida claims evidence map",{"type":58,"value":59,"toc":135},"minimark",[60,68,74,80,86,92,98,104,110,116,122],[61,62,64],"content-section",{"section-key":10,"title":63},"Bottom line",[65,66,67],"p",{},"Adding probiotics to antifungals produced small short-term signals, but the evidence did not establish durable benefit and did not include recurrent or higher-risk populations.",[61,69,71],{"section-key":11,"title":70},"Why this source matters",[65,72,73],{},"It separates short-term adjunct results from durable outcomes, recurrence prevention, monotherapy, and product-specific claims.",[61,75,77],{"section-key":12,"title":76},"Study and population",[65,78,79],{},"The review included 10 randomized trials and 1,656 nonpregnant outpatients with VVC; recurrent VVC and several higher-risk groups were excluded.",[61,81,83],{"section-key":13,"title":82},"What was tested",[65,84,85],{},"Every trial compared probiotics used alongside conventional antifungals with conventional antifungals alone.",[61,87,89],{"section-key":14,"title":88},"Results",[65,90,91],{},"Short-term clinical resolution occurred in 286/347 versus 251/348 participants. One-month relapse occurred in 10/202 versus 27/186, but long-term clinical and mycological resolution were not clearly improved.",[61,93,95],{"section-key":15,"title":94},"Applicability",[65,96,97],{},"The result concerns adjunct treatment for nonpregnant people with VVC, not recurrent VVC prevention, monotherapy, pregnancy, higher-risk groups, or every probiotic product.",[61,99,101],{"section-key":16,"title":100},"Limitations",[65,102,103],{},"Evidence was low or very low certainty, trials had bias and imprecision, and durable, cost, and strain-specific evidence was inadequate.",[61,105,107],{"section-key":17,"title":106},"Contribution to the evidence",[65,108,109],{},"Supporting. The review supplies auditable short-term estimates while defining the important durability and population gaps.",[61,111,113],{"section-key":18,"title":112},"Practical change",[65,114,115],{},"No practical change. The review does not justify a durable-benefit claim or selection of a probiotic product.",[61,117,119],{"section-key":19,"title":118},"Funding and conflicts",[65,120,121],{},"None of the ten trials reported pharmaceutical-industry funding. One included trial reported a lactobacilli-related patent interest; no review-level author conflict was identified in the accessible record.",[61,123,125],{"section-key":20,"title":124},"Source",[65,126,127,134],{},[128,129,133],"a",{"href":130,"rel":131},"https://pmc.ncbi.nlm.nih.gov/articles/PMC6486023/",[132],"nofollow","Read the original Cochrane review"," (published 23 November 2017).",{"title":136,"searchDepth":137,"depth":137,"links":138},"",2,[],{"sources":140,"claims":147,"safety":148},[141],{"sourceId":27,"title":142,"canonicalId":143,"canonicalUrl":144,"publisher":145,"sourceType":146,"publicationDate":36,"lastChecked":24},"Probiotics for vulvovaginal candidiasis in non-pregnant women","CD010496; DOI:10.1002/14651858.CD010496.pub2","https://www.cochrane.org/evidence/CD010496_probiotics-vulvovaginal-candidiasis-non-pregnant-women","Cochrane Database of Systematic Reviews","systematic-review",[],[],[150,153,156],{"rel":151,"hreflang":6,"href":152},"alternate","https://candipedia.org/en/research/probiotics-for-vvc-cochrane-2017/",{"rel":151,"hreflang":154,"href":155},"pl-PL","https://candipedia.org/pl/research/probiotyki-w-vvc-przeglad-cochrane-2017/",{"rel":151,"hreflang":157,"href":152},"x-default",1784685064837]